The selective peroxisome proliferator-activated receptor alpha modulator (SPPARMα) paradigm: conceptual framework and therapeutic potential : A consensus statement from the International Atherosclerosis Society (IAS) and the Residual Risk Reduction Initiative (R3i) Foundation

In the era of precision medicine, treatments that target specific modifiable characteristics of high-risk patients have the potential to lower further the residual risk of atherosclerotic cardiovascular events. Correction of atherogenic dyslipidemia, however, remains a major unmet clinical need. Ele...

Full description

Saved in:

Bibliographic Details
Published in:	Cardiovascular diabetology Vol. 18; no. 1; p. 71
Main Authors:	Fruchart, Jean-Charles, Santos, Raul D, Aguilar-Salinas, Carlos, Aikawa, Masanori, Al Rasadi, Khalid, Amarenco, Pierre, Barter, Philip J, Ceska, Richard, Corsini, Alberto, Després, Jean-Pierre, Duriez, Patrick, Eckel, Robert H, Ezhov, Marat V, Farnier, Michel, Ginsberg, Henry N, Hermans, Michel P, Ishibashi, Shun, Karpe, Fredrik, Kodama, Tatsuhiko, Koenig, Wolfgang, Krempf, Michel, Lim, Soo, Lorenzatti, Alberto J, McPherson, Ruth, Nuñez-Cortes, Jesus Millan, Nordestgaard, Børge G, Ogawa, Hisao, Packard, Chris J, Plutzky, Jorge, Ponte-Negretti, Carlos I, Pradhan, Aruna, Ray, Kausik K, Reiner, Željko, Ridker, Paul M, Ruscica, Massimiliano, Sadikot, Shaukat, Shimano, Hitoshi, Sritara, Piyamitr, Stock, Jane K, Su, Ta-Chen, Susekov, Andrey V, Tartar, André, Taskinen, Marja-Riitta, Tenenbaum, Alexander, Tokgözoğlu, Lale S, Tomlinson, Brian, Tybjærg-Hansen, Anne, Valensi, Paul, Vrablík, Michal, Wahli, Walter, Watts, Gerald F, Yamashita, Shizuya, Yokote, Koutaro, Zambon, Alberto, Libby, Peter
Format:	Journal Article
Language:	English
Published:	England BioMed Central 04-06-2019
Subjects:	Animals Benzoxazoles - adverse effects Benzoxazoles - therapeutic use Biomarkers - blood Butyrates - adverse effects Butyrates - therapeutic use Cardiovascular Diseases - blood Cardiovascular Diseases - diagnosis Cardiovascular Diseases - prevention & control Consensus Dyslipidemias - blood Dyslipidemias - diagnosis Dyslipidemias - drug therapy Humans Hypolipidemic Agents - adverse effects Hypolipidemic Agents - therapeutic use Lipids - blood Molecular Targeted Therapy Patient Safety PPAR alpha - agonists PPAR alpha - metabolism Review Risk Assessment Risk Factors Signal Transduction Treatment Outcome Atherogenic dyslipidemia SPPARMalpha Selective peroxisome proliferator-activated receptor alpha modulator Residual cardiovascular risk Inflammation Pemafibrate (K-877) Triglycerides Diabetes PROMINENT Remnant cholesterol Visceral obesity
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!